Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients

Antimicrob Agents Chemother. 2004 Aug;48(8):3151-3. doi: 10.1128/AAC.48.8.3151-3153.2004.


The pharmacokinetics of intravenous itraconazole (ITC) was studied in dialysis patients. Dialysis had no effect on the half-life and clearance of ITC or OH-ITC. However, dialysis allowed the clearance of hydroxypropyl-beta-cyclodextrin (HP-beta-CD). The area under the concentration-time curve from time zero to infinity (AUC(0- infinity)) for HP-beta-CD administered before dialysis was lower than the AUC(0- infinity) when it was administered after dialysis (P < 0.01). Administration of ITC intravenously just prior to hemodialysis appears to produce adequate systemic exposures of ITC and OH-ITC while allowing dialysis clearance of HP-beta-CD. Studies of multiple administrations are warranted.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Hydroxypropyl-beta-cyclodextrin
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacokinetics*
  • Area Under Curve
  • Calibration
  • Cyclodextrins / pharmacokinetics
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Itraconazole / administration & dosage
  • Itraconazole / pharmacokinetics*
  • Kidney Failure, Chronic / metabolism
  • Renal Dialysis*
  • beta-Cyclodextrins*


  • Antifungal Agents
  • Cyclodextrins
  • beta-Cyclodextrins
  • 2-Hydroxypropyl-beta-cyclodextrin
  • Itraconazole